Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address high unmet medical needs and improve the lives of patients. The company's mission is rooted in scientific rigor and patient-centric innovation, primarily focusing on central nervous system (CNS) disorders and rare diseases. Headquartered in Washington, D.C., USA, Vanda Pharmaceuticals operates from 2200 Pennsylvania Avenue Northwest, Suite 300E.

Vanda's commercial portfolio includes several key products. HETLIOZ (tasimelteon) is approved for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome. Fanapt (iloperidone) is utilized for the treatment of schizophrenia and bipolar I disorder. PONVORY (ponesimod) addresses inflammatory/autoimmune disorders, including multiple sclerosis. Most recently, the company launched NEREUS (tradipitant) for the prevention of vomiting induced by motion in adults.

In recent news, Vanda Pharmaceuticals announced the commercial availability of NEREUS (tradipitant) in the U.S. in May 2026, marking the first new pharmacologic treatment for motion sickness in over 40 years, following its FDA approval on December 30, 2025. The company continues to advance its pipeline, with NEREUS also in clinical development for gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Mihael H. Polymeropoulos, MD, serves as the President, CEO, and Chairman of the Board, having founded the company in 2003. Vanda Pharmaceuticals is positioned as a small-cap biopharmaceutical firm with a strategic focus on high-risk, high-reward drug development in niche patient populations, with recent product launches and a robust pipeline expected to contribute to future growth and a transition towards profitability.

Latest updates

Vanda Launches NEREUS™ with Direct-to-Consumer Model, Targets $65M Motion Sickness Market

Event summary

  • Vanda Pharmaceuticals launched NEREUS™ (tradipitant), a new prescription drug for the prevention of motion sickness, on May 1, 2026.
  • The drug, approved by the FDA on December 30, 2025, is the first new treatment for motion sickness in over 40 years.
  • Vanda is utilizing a direct-to-consumer (DTC) sales model via nereus.us, offering a $85/dose cash price compared to a $255 list price.
  • Motion sickness affects an estimated 65-78 million Americans, representing a roughly $65 million market opportunity.

The big picture

Vanda’s launch of NEREUS™ represents a strategic shift towards direct-to-consumer sales in a traditionally pharmacy-driven pharmaceutical market. The drug’s efficacy and novel mechanism of action address a significant unmet need, but the DTC model introduces new operational and regulatory complexities. The historical context of motion sickness impacting military and space exploration underscores the potential for broader applications beyond everyday travel.

What we're watching

DTC Adoption
The success of Vanda’s DTC model will hinge on patient acquisition costs and the ability to bypass traditional pharmacy channels, potentially disrupting established distribution networks.
Competitive Response
Existing over-the-counter remedies and potential generic entrants will likely challenge NEREUS™’s market share, requiring Vanda to demonstrate sustained clinical and economic value.
Expansion Potential
Vanda’s stated plans to explore NEREUS™ for gastroparesis and GLP-1 agonist-induced nausea will determine the drug’s long-term revenue trajectory and pipeline value.

Vanda Publishes Phase III Data for GPP Drug, Awaits FDA Decision

Event summary

  • Vanda Pharmaceuticals published results from a Phase III clinical trial for imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP), in NEJM Evidence.
  • The trial data is part of a Biologics License Application (BLA) submitted to the FDA, with a target action date of December 12, 2026.
  • Imsidolimab is a fully humanized IgG4 monoclonal antibody targeting the IL-36 receptor.
  • Vanda holds an exclusive global license for imsidolimab from AnaptysBio.

The big picture

The publication of positive Phase III data for imsidolimab represents a critical milestone for Vanda, positioning the company to address a significant unmet medical need in a niche market. GPP is a debilitating and rare condition, and successful approval of imsidolimab could provide Vanda with a valuable, albeit limited, revenue stream. The deal with AnaptysBio underscores the trend of larger biopharma companies licensing out early-stage assets to focus on core pipelines.

What we're watching

Regulatory Risk
The FDA’s decision on the BLA, scheduled for December 2026, represents a significant near-term catalyst for Vanda’s valuation, and potential delays or rejection would be detrimental.
Commercialization
Given GPP's rarity, Vanda's ability to effectively market and distribute imsidolimab, if approved, will be crucial for achieving commercial success and justifying the development investment.
Patent Landscape
The projected patent exclusivity extending into the late 2030s is a key value driver, and any challenges to these patents or emergence of biosimilars could significantly impact long-term revenue potential.
CID: 1528